Attacking malignant cells that survive therapy: Exploiting immunogenic modulation

We have recently defined “immunogenic modulation,” a mechanism whereby malignant cells that survive anticancer therapy, due to sublethal delivery or development of treatment resistance, become nonetheless more sensitive to killing by cytotoxic T lymphocytes. This mechanism can be exploited to identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodge, James W, Kwilas, Anna, Ardiani, Andressa, Gameiro, Sofia R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902115/
https://www.ncbi.nlm.nih.gov/pubmed/24498561
http://dx.doi.org/10.4161/onci.26937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902115/
https://www.ncbi.nlm.nih.gov/pubmed/24498561
http://dx.doi.org/10.4161/onci.26937

Ejemplares similares